Press Release
Techniclone to Participate in Domestic and International Biotechnology Conferences
Road Show Activities to Accelerate to Seattle, San Francisco, Miami, Charlotte and Atlanta Through Mid-October
TUSTIN, Calif.--(BUSINESS WIRE)--Sept. 11, 2000-- Techniclone Corporation (Nasdaq:TCLN - news) today announced that the company has been invited to attend four significant industry conferences. They include the Stephens Biotechnology Conference from Sept. 17 through 19 in San Francisco, the UBS Warburg Global Life Sciences Conference in New York, from Oct. 2 through Oct. 4, 1st European C21 Investor Conference in London, on Oct. 19 and The Wall Street Analyst Forum 38th Investor Conference in New York City from Feb. 13 through Feb. 15. Each offers a forum for biotechnology companies to present fundamentals and progress to large forums of members of the investment community. Dr. Bonfiglio will be speaking at the Stephens Conference and the European C21 Investor Conference in London and the Wall Street Analyst Conference in New York City.
In conjunction with attendance at these conferences Techniclone management will continue their road show activities targeting the following cities: Seattle, San Francisco, Miami, Charlotte and Atlanta. Details of specific venues, dates commencing at the end of September through mid-October, and meetings are presently being planned.
Dr. John Bonfiglio, president and CEO, stated, ``Techniclone's platform technologies are beginning to get the recognition they deserve. The fact that the company is being invited to attend and speak at major conferences along with other biotechnology and major pharmaceutical companies indicates acceptance and agreement by industry experts on our strategy to aggressively develop these important technologies. Additionally, our commitment to target key industry analysts and fund managers is reflected in the company's aggressive road show schedule. It is with great enthusiasm that we continue to lay firm foundations and create key alliances with investment professionals who, we contend, will see Techniclone as undervalued and an excellent investment opportunity.''
Company overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ``collateral targeting technologies.'' These technologies are intended to target cell structures and cell types, rather than the surface of cancer cells, as a means to attack solid tumors without causing damage to surrounding healthy tissue. The company has three collateral technologies which are currently in various stages of development: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The company also has a direct tumor targeting agent known as Oncolym® which is currently in clinical trials for the treatment of advanced non-Hodgkins B-cell Lymphoma. Oncolym® has been licensed to Schering AG, Germany, which is now responsible for all existing and future clinical trial programs as well as marketing upon FDA approval.
Additional information on the company and its technologies can be found at www.techniclone.com.
|
Thread abonnieren
